Vanguard Group Inc Viracta Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 954,485 shares of VIRX stock, worth $238,621. This represents 0.0% of its overall portfolio holdings.
Number of Shares
954,485
Previous 1,161,280
17.81%
Holding current value
$238,621
Previous $627,000
65.07%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding VIRX
# of Institutions
41Shares Held
5.63MCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.52MShares$380,0600.0% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA690KShares$172,4270.09% of portfolio
-
Stonepine Capital Management, LLC Bend, OR500KShares$125,0000.07% of portfolio
-
Laurion Capital Management LP New York, NY332KShares$83,0470.0% of portfolio
-
Aisling Capital Management LP New York, NY289KShares$72,1420.03% of portfolio
About Viracta Therapeutics, Inc.
- Ticker VIRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,558,200
- Market Cap $9.39M
- Description
- Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...